^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Excerpt:
Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases...
DOI:
10.1158/2159-8290.CD-17-1119
Trial ID:
